Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
(CST-2032 + nadolol) by CuraSen Therapeutics for Dementia: Likelihood of Approval
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia. According to GlobalData,...
(CST-2032 + nadolol) by CuraSen Therapeutics for Mild Cognitive Impairment: Likelihood of Approval
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Mild Cognitive Impairment. According...
(CST-2032 + nadolol) by CuraSen Therapeutics for Dementia Associated With Alzheimer's Disease: Likelihood of Approval
(CST-2032 + nadolol) is under clinical development by CuraSen Therapeutics and currently in Phase II for Dementia Associated With Alzheimer's...